Skip to main content
CAMBIUM BIO LIMITED logo

CAMBIUM BIO LIMITED — Investor Relations & Filings

Ticker · CMB ISIN · AU0000327769 ASX Professional, scientific and technical activities
Open in API
Filings indexed 504 across all filing types
Latest filing 2023-02-27 Capital/Financing Update
Country AU Australia
Listing ASX CMB

About CAMBIUM BIO LIMITED

https://www.cambium.bio

Cambium Bio Limited is a clinical-stage regenerative medicine company focused on developing innovative cellular therapies to treat unmet medical needs in ophthalmology and inflammatory diseases. The company's primary focus is on its lead candidate, EluRegen, a first-in-class topical biologic designed for the treatment of corneal epithelial defects and dry eye disease. Utilizing its proprietary technology platforms, the company aims to harness the regenerative potential of biologics to provide effective treatments for chronic conditions. In addition to its ophthalmic pipeline, the company maintains assets in the field of mesenchymal stem cell therapies, including Progenza, which targets osteoarthritis and neuropathic pain. The company emphasizes a data-driven approach to clinical development, seeking to improve patient outcomes through advanced tissue engineering and cell-based solutions.

Recent filings

Filing Released Lang Actions
Regeneus agrees to settle $2m loan 2 pages 135.4KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 28 February 2023 regarding the settlement of a $2.0 million loan, disposal of non-core assets, financial position update, ongoing discussions with Kyocera Corporation, search for strategic partners, and exploration of M&A options. It primarily provides updates on financing arrangements, strategic transactions, and operational matters. There are no detailed financial statements or comprehensive financial performance data typical of an Annual Report or Interim Report. The document is not a call transcript, audit report, or governance information. It is a corporate announcement about financing and strategic updates, fitting best under Capital/Financing Update (CAP). The document length (5786 characters) and content confirm it is a substantive announcement rather than a brief notice or report publication announcement.
2023-02-27 English
Half Yearly Report and Accounts 21 pages 1.5MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'ASX Half-Year Report for 6 months to 31 December 2022' and includes detailed financial statements, directors' report, auditor's independence declaration, consolidated financial statements, and notes. It covers a half-year period and contains substantive financial data and analysis, including revenue, profit/loss, cash flows, and operational details. The presence of an auditor's review report and detailed financial disclosures confirms it is a comprehensive interim financial report. The document is not a brief announcement or a certification letter but a full half-year report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-02-27 English
Notice of Termination of Kyocera Licence 3 pages 135.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 31 January 2022 regarding the termination notice of a license agreement between Regeneus and Kyocera. It discusses the background of the agreement, the purported termination by Kyocera, Regeneus' position disputing the termination, and ongoing dispute resolution. The content is a corporate announcement about a contractual dispute and termination notice, not a financial report, earnings release, or regulatory filing of financial data. It does not contain financial statements or detailed financial analysis. It is not a report publication announcement since it is a substantive announcement about a material event affecting the company. The document fits best into the category of Regulatory Filings (RNS) as a general regulatory announcement about a material contract termination and dispute.
2023-01-30 English
Quarterly Activities/Appendix 4C Cash Flow Report 7 pages 335.7KB
Interim / Quarterly Report Classification · 100% confidence The document is an ASX announcement dated 31 January 2023, titled 'Quarterly Cashflow Report & Business Update – Period ending 31 December 2022'. It includes detailed financial data such as consolidated statements of cash flows for the quarter and year to date, payments to related parties, financing facilities, and estimated cash available for future operating activities. The document references compliance with ASX Listing Rule 4.7B and includes an Appendix 4C quarterly cash flow report, which is a standard regulatory filing for Australian listed entities to report quarterly cash flows and activities. The document is about 15,000 characters long, contains substantive financial data, and is not merely an announcement of a report or a certification. It is a comprehensive quarterly financial report covering a period shorter than a full fiscal year, consistent with the definition of an Interim / Quarterly Report (IR). Q2 2022
2023-01-30 English
Trading Halt 2 pages 180.0KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Regeneus Limited regarding a trading halt requested under ASX Listing Rule 17.1. It states the halt is pending an announcement about a Licence and Collaboration Agreement with Kyocera. The document is short (1987 characters) and does not contain any financial data, results, or detailed report content. It is an announcement about a trading halt, not a financial report or detailed disclosure. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2023-01-29 English
Regeneus receives $1.1 million R&D Tax Incentive Refund 1
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 20 December 2022, informing about Regeneus Ltd receiving a $1.1 million R&D Tax Incentive Refund from the Australian Tax Office for activities in the 2022 financial year. The announcement discusses the use of funds and provides company background and contact information. The document is short (1809 characters) and serves as a news update rather than a detailed financial report or regulatory filing. It does not contain financial statements, management discussion, or detailed report data. It is an announcement of a financing-related event (receipt of a tax refund) but not a comprehensive capital or financing update report. Given the nature and length, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-12-19 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.